<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://teaching.ncl.ac.uk/bms/wiki//index.php?action=history&amp;feed=atom&amp;title=Trastuzumab</id>
	<title>Trastuzumab - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://teaching.ncl.ac.uk/bms/wiki//index.php?action=history&amp;feed=atom&amp;title=Trastuzumab"/>
	<link rel="alternate" type="text/html" href="https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;action=history"/>
	<updated>2026-04-13T12:55:42Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.0</generator>
	<entry>
		<id>https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=20548&amp;oldid=prev</id>
		<title>Nnjm2: Cleaned up the references.</title>
		<link rel="alternate" type="text/html" href="https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=20548&amp;oldid=prev"/>
		<updated>2017-12-06T20:29:11Z</updated>

		<summary type="html">&lt;p&gt;Cleaned up the references.&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 20:29, 6 December 2017&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Trastuzumab, known more commonly as [[Herceptin|Herceptin]], is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as HER2 positive&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.&amp;amp;nbsp;&lt;/del&gt;&amp;lt;ref&amp;gt;NHS choices,2014,Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;amp;nbsp;&lt;/del&gt;However, not all cancer patients are HER2 positive, for example, only 25% of breast cancers have HER2 mutation.&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;amp;nbsp;&lt;/del&gt;Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;herceptin &lt;/del&gt;causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;amp;nbsp;&lt;/del&gt;&amp;lt;ref&amp;gt;Breast Cancer Care,2014,Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;. This treatment process is a type of targeted therapy (when a drug targets a specific gene or protein). It has a big impact in treating cancer: Herceptin helps to prevent relapse &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;in &lt;/del&gt;an early stage of breast cancer and make patient&#039;s survival time longer if the stage is advanced. However, only targeted therapy is not enough in the whole treatment process, chemotherapy or radiology have to be used as well&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;&amp;lt;ref&amp;gt;National Health Service. Herceptin (trastuzumab). 2016. https://www.nhs.uk/conditions/herceptin/ (accessed 20 November 2017)&amp;lt;/ref&amp;gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Trastuzumab, known more commonly as [[Herceptin|Herceptin]], is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as HER2 positive&amp;lt;ref&amp;gt;NHS choices,2014, Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;. &lt;/ins&gt;However, not all cancer patients are HER2 positive, for example, only 25% of breast cancers have HER2 mutation. Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Herceptin &lt;/ins&gt;causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to&amp;lt;ref&amp;gt;Breast Cancer Care,2014, Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;. This treatment process is a type of targeted therapy (when a drug targets a specific gene or protein). It has a big impact in treating cancer: Herceptin helps to prevent relapse &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;at &lt;/ins&gt;an early stage of breast cancer and make patient&#039;s survival time longer if the stage is advanced. However, only targeted therapy is not enough in the whole treatment process, chemotherapy or radiology have to be used as well&amp;lt;ref&amp;gt;National Health Service. Herceptin (trastuzumab). 2016. https://www.nhs.uk/conditions/herceptin/ (accessed 20 November 2017)&amp;lt;/ref&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;. &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;=== References &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;=== References ===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;gt;&amp;lt;u&amp;gt;&amp;lt;/u&lt;/del&gt;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Nnjm2</name></author>
	</entry>
	<entry>
		<id>https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=20487&amp;oldid=prev</id>
		<title>170422336 at 12:52, 6 December 2017</title>
		<link rel="alternate" type="text/html" href="https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=20487&amp;oldid=prev"/>
		<updated>2017-12-06T12:52:05Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 12:52, 6 December 2017&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Trastuzumab, known more commonly as [[Herceptin|Herceptin]], is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HEF2 &lt;/del&gt;positive.&amp;amp;nbsp;&amp;lt;ref&amp;gt;NHS choices,2014,Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&amp;amp;nbsp;Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, herceptin causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to&amp;amp;nbsp;&amp;lt;ref&amp;gt;Breast Cancer Care,2014,Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;.&amp;lt;br&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Trastuzumab, known more commonly as [[Herceptin|Herceptin]], is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HER2 &lt;/ins&gt;positive.&amp;amp;nbsp;&amp;lt;ref&amp;gt;NHS choices,2014,Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;amp;nbsp;However, not all cancer patients are HER2 positive, for example, only 25% of breast cancers have HER2 mutation.&lt;/ins&gt;&amp;amp;nbsp;Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, herceptin causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to&amp;amp;nbsp;&amp;lt;ref&amp;gt;Breast Cancer Care,2014,Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;. &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;This treatment process is a type of targeted therapy (when a drug targets a specific gene or protein). It has a big impact in treating cancer: Herceptin helps to prevent relapse in an early stage of breast cancer and make patient&#039;s survival time longer if the stage is advanced. However, only targeted therapy is not enough in the whole treatment process, chemotherapy or radiology have to be used as well.&amp;lt;ref&amp;gt;National Health Service. Herceptin (trastuzumab). 2016. https://www.nhs.uk/conditions/herceptin/ (accessed 20 November 2017)&amp;lt;/ref&amp;gt;&lt;/ins&gt;&amp;lt;br&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;=== References  ===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;=== References  ===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&amp;gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&amp;gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>170422336</name></author>
	</entry>
	<entry>
		<id>https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=11994&amp;oldid=prev</id>
		<title>Nnjm2 at 12:49, 25 November 2014</title>
		<link rel="alternate" type="text/html" href="https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=11994&amp;oldid=prev"/>
		<updated>2014-11-25T12:49:45Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 12:49, 25 November 2014&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;amp;nbsp;&lt;/del&gt;Trastuzumab, known more commonly as Herceptin, is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as HEF2 positive.&amp;amp;nbsp;&amp;lt;ref&amp;gt;NHS choices,2014,Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&amp;amp;nbsp;Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, herceptin causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.&lt;/del&gt;&amp;amp;nbsp;&amp;lt;ref&amp;gt;Breast Cancer Care,2014,Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Trastuzumab, known more commonly as &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[&lt;/ins&gt;Herceptin&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|Herceptin]]&lt;/ins&gt;, is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as HEF2 positive.&amp;amp;nbsp;&amp;lt;ref&amp;gt;NHS choices,2014,Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&amp;amp;nbsp;Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, herceptin causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to&amp;amp;nbsp;&amp;lt;ref&amp;gt;Breast Cancer Care,2014,Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;gt;.&amp;lt;br&lt;/ins&gt;&amp;gt;  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;=== &lt;/ins&gt;References &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt; ===&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt; &lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;u&amp;gt;&lt;/del&gt;References&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/u&amp;gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&amp;gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&amp;gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Nnjm2</name></author>
	</entry>
	<entry>
		<id>https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=11967&amp;oldid=prev</id>
		<title>130300885: Created page with &quot;&amp;nbsp;Trastuzumab, known more commonly as Herceptin, is a medicine used to treat some breast and stomach cancers. The human epidermal growth factor r...&quot;</title>
		<link rel="alternate" type="text/html" href="https://teaching.ncl.ac.uk/bms/wiki//index.php?title=Trastuzumab&amp;diff=11967&amp;oldid=prev"/>
		<updated>2014-11-25T10:28:41Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot; Trastuzumab, known more commonly as Herceptin, is a medicine used to treat some &lt;a href=&quot;/bms/wiki/index.php/Breast_Cancer&quot; title=&quot;Breast Cancer&quot;&gt;breast&lt;/a&gt; and stomach &lt;a href=&quot;/bms/wiki/index.php/Cancer&quot; title=&quot;Cancer&quot;&gt;cancers&lt;/a&gt;. The human epidermal growth factor r...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;amp;nbsp;Trastuzumab, known more commonly as Herceptin, is a medicine used to treat some [[Breast Cancer|breast]] and stomach [[Cancer|cancers]]. The human epidermal growth factor receptor 2 is a [[Protein|protein]] present in ordinary human cells. The levels of this protein are abnormally high in [[Cancer|cancer]] patients; therefore they are known as HEF2 positive.&amp;amp;nbsp;&amp;lt;ref&amp;gt;NHS choices,2014,Herceptin.[online]Available at:http://www.nhs.uk/conditions/herceptin/Pages/Introduction.aspx[Accessed 25 November 2014]&amp;lt;/ref&amp;gt;&amp;amp;nbsp;Herceptin attaches itself to the HER2 receptors on the surface of cancer cells; therefore blocking these [[Cell|cells]] from any growth signals they may have otherwise received. After this attachment, herceptin causes the [[Immune system|immune system]] to kill the cancer cells that it is attached to.&amp;amp;nbsp;&amp;lt;ref&amp;gt;Breast Cancer Care,2014,Herceptin[online]Available at:https://www.breastcancercare.org.uk/breast-cancer-information/treating-breast-cancer/targeted-therapy/trastuzumab-herceptin[Accessed 25 November 2014]&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;u&amp;gt;References&amp;lt;/u&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&amp;lt;references /&amp;gt;&amp;lt;u&amp;gt;&amp;lt;/u&amp;gt;&lt;/div&gt;</summary>
		<author><name>130300885</name></author>
	</entry>
</feed>